CompletedNCT00970281
A Study of Olanzapine in Patients With Schizophrenia
Researchers compared Rapid-Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 20–64Japan
Understand this study
What did researchers investigate?
Researchers compared Rapid-Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Aichi and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 91
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 20 Years to 64 Years
- Official registry ID
- NCT00970281
- Official title
Show the full official title
A Double-Blind Confirmatory Study Comparing Rapid-Acting Intramuscular Olanzapine and Rapid-Acting Intramuscular Placebo in Patients With an Exacerbation of Schizophrenia With Acute Psychotic Agitation
Get this study by email
Recruitment & locations
CompletedAichi · Gunma · Hokkaido
8 more locations
- Kanagawa
- Kumamoto
- Nara
- Okinawa
- Osaka
- Saitama
- Tokyo
- Yamaguchi
Questions about this study
What did researchers investigate?
Researchers compared Rapid-Acting Intramuscular Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Rapid-Acting Intramuscular Olanzapine and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.
